Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update

Background: Primary analysis of the phase I/II clinical trial combining pembrolizumab with all-trans retinoic acid (ATRA) for patients with metastatic melanoma showed a median progression-free survival (PFS) of 20.3 months and median overall survival (OS) not reached. Objective: Report 5-year OS and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jessica S. W. Borgers, Theresa M. Medina, William A. Robinson, Kasey L. Couts, Elizabeth N. Katsnelson, Claire M. Muckle, Eduardo Davilla, Sapna P. Patel, Dexiang Gao, Richard P. Tobin, Martin D. McCarter
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-06-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359251349321
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

All -Trans-Retinoic Acid–induced pseudotumor cerebri in Acute Promyelocytic Leukemia
by: anoop tm
Published: (2014-08-01)

Multiplex metabolic engineering of yeast for high-efficiency all-trans-retinoic acid production
by: Wenhao Li, et al.
Published: (2025-07-01)

IS ALL-TRANS RETINOIC ACID EFFECTIVE IN PULMONARY HAEMORRHAGE IN PATIENTS WITH ACUTE PROMYELOBLASTIC LEUKAEMIA?
by: Süleyman Atay, et al.
Published: (2024-12-01)

Combination of arsenicum trioxide and all trans retinoic acid in the treatment of relapsed acute promyelocytic leukemia
by: A. N. Sokolov, et al.
Published: (2015-06-01)

Effects of all-trans retinoic acid and oxygen concentration on the proliferation and differentiation of subcutaneous adipocytes in yak
by: Sibinuer Yasenjian, et al.
Published: (2025-08-01)

Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma
by: Erica Martel, et al.
Published: (2025-01-01)

Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia
by: Bingqian Jiang, et al.
Published: (2025-07-01)

Effects of all-trans retinoic acid on glutamate receptor expression and dendritic spine density in the hypothalamus of rats
by: Yuan-Zhong Kai, et al.
Published: (2025-08-01)

Comparative Analysis of Pembrolizumab Dosing Schedules in the Adjuvant Treatment of Malignant Melanoma
by: Y. Ahmed, et al.
Published: (2024-01-01)

All-Trans Retinoic Acid Induces Differentiation and Downregulates Stemness Markers and MGMT Expression in Glioblastoma Stem Cells
by: Justin Tang, et al.
Published: (2025-05-01)

Notch3 enhances the synergistic effect of all-trans retinoic acid and calcipotriol in pancreatic stellate cell activation
by: Zheng Lian, et al.
Published: (2025-06-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01)

WCN24-944 All-trans retinoic acid enhances the efficacy of mesenchymal stem cells in acute kidney injury
by: Yifan Zhang
Published: (2024-04-01)

Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma
by: Merve Hasanov, et al.
Published: (2025-12-01)

Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis
by: Matthew Zibelman, et al.
Published: (2017-08-01)

Bradycardia during Induction Therapy with All-trans Retinoic Acid in Patients with Acute Promyelocytic Leukemia: Case Report and Literature Review
by: Pin-Zi Chen, et al.
Published: (2018-01-01)

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
by: Ramses Sadek, et al.
Published: (2021-06-01)

Enhancing human osteoblast to osteocyte-like cell differentiation using 25-hydroxyvitamin D3 and all-trans retinoic acid combination
by: A Munir, et al.
Published: (2025-06-01)

Acute promyelocytic leukemia with <i>TTMV::RARA</i> fusion potentially responds to all-trans retinoic acid/arsenic trioxide treatment
by: Qingyu Xu, et al.
Published: (2025-01-01)

Enhanced therapeutic effects of all-trans retinoic acid nanostructured lipid carrier composite gel drug delivery system for alopecia areata
by: Lingling Zheng, et al.
Published: (2025-05-01)

All-Trans Retinoic Acid Drives Development Phase- Specific Response to Adipogenic and Myogenic Processes in Bovine Skeletal Muscle-Derived Cells
by: Brad Kim, et al.
Published: (2024-02-01)

The Vitamin A Derivative All-Trans Retinoic Acid Repairs Amyloid-β-Induced Double-Strand Breaks in Neural Cells and in the Murine Neocortex
by: Emmanuelle Gruz-Gibelli, et al.
Published: (2016-01-01)

Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission
by: Richard Carvajal, et al.
Published: (2021-10-01)

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
by: Michael Weichenthal, et al.
Published: (2024-12-01)

Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK
by: Alfred CP So, et al.
Published: (2018-03-01)

An update on adjuvant systemic therapies in melanoma
by: Evangeline Samuel, et al.
Published: (2019-11-01)

Trans-femoral versus trans-carotid access for transcatheter aortic valve replacement: an updated systematic review and meta-analysis
by: Naser Yamani, et al.
Published: (2024-12-01)

A seven-year electroretinography follow-up of a patient with melanoma-associated retinopathy stabilized on pembrolizumab treatment
by: Raz Tshuva-Bitton, et al.
Published: (2025-06-01)

Screening and novel diagnostic technologies for melanoma: an update
by: Jonathan C. Hwang, et al.
Published: (2025-07-01)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
by: Alessio Cortellini, et al.
Published: (2018-01-01)

Acute Coronary Syndrome Manifesting as an Adverse Effect of All-trans-Retinoic Acid in Acute Promyelocytic Leukemia: A Case Report with Review of the Literature and a Spotlight on Management
by: K. Govind Babu, et al.
Published: (2016-01-01)

RETRACTED ARTICLE: ω-3 free fatty acids and all-trans retinoic acid synergistically induce growth inhibition of three subtypes of breast cancer cell lines
by: Guangxiao Lin, et al.
Published: (2017-06-01)

Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All Trans Retinoic Acid: A Monocentric Experience.
by: Francesco Autore, et al.
Published: (2023-01-01)

Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
by: G. Lyrarakis, et al.
Published: (2024-01-01)

Pembrolizumab: The nut cracker
by: Gangothri Selvarajan
Published: (2020-01-01)

Smouldering Malignant Melanoma and Metastatic Dormancy: An Update and Review
by: Gérald E. Piérard, et al.
Published: (2012-01-01)

Advanced Melanoma: Updated Results from Ongoing Trials
by: Egle Ramelyte, et al.
Published: (2024-10-01)

All-Trans Retinoic Acid Induces CD4+CD25+FOXP3+ Regulatory T Cells by Increasing FOXP3 Demethylation in Systemic Sclerosis CD4+ T Cells
by: Xiaohong Sun, et al.
Published: (2018-01-01)

Effect of retinoic acid treatment on the retinoic acid signaling pathway in a human siRNA-based aniridia limbal epithelial cell model, in vitro.
by: Shao-Lun Hsu, et al.
Published: (2025-01-01)

Effect of retinoic acid treatment on the retinoic acid signaling pathway in a human siRNA-based aniridia limbal epithelial cell model, in vitro
by: Shao-Lun Hsu, et al.
Published: (2025-01-01)